


CLAIMS

What is claimed is:

- 5 1. A compound of Formula (I)



(I)

wherein:

10

R¹ is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and is unsubstituted or substituted with 1-2 substituents selected from the group consisting of halogen, C₁₋₆alkyl, trifluoromethyl, C₁₋₆alkoxy, trifluoromethoxy, and cyano;

15

R² is hydrogen or C₁₋₆alkyl;

R³ is selected from the group consisting of isopropyl, tert-butyl, sec-butyl, and C(CH₃)₂SCH₃;

20

R⁴ is phenyl, indazolyl, benzothiazolyl, quinolinyl, quinoxalinyl, 2,3-dihydrobenzofuranyl, or 1,3-benzodioxolyl, and is unsubstituted or substituted with 1-2 substituents selected from the group consisting of amino, acetamido, halo, C₁₋₆alkyl, trifluoromethyl, C₁₋₆alkoxy, trifluoromethoxy, and cyano; and

25

m is 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein R¹ is phenyl,
3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl,
5 2,4-difluorophenyl, 2,6-difluorophenyl,
3-trifluoromethylphenyl, 3-pyridinyl, or 3-methoxyphenyl.

3. A compound of claim 2 where R¹ is phenyl,
3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl,
10 3-trifluoromethylphenyl, 3-pyridinyl, or 3-methoxyphenyl.

4. A compound of claim 1 where R² is hydrogen or
methyl.


- 15 5. A compound according to Claim 1 wherein R⁴ is
selected from the group consisting of 4-aminophenyl, 3-
aminophenyl, 3-amino-4-methylphenyl, 4-methoxyphenyl,
6-benzothiazolyl, 2-amino-6-benzothiazolyl,
2-acetamido-6-benzothiazolyl, 2-methyl-6-benzothiazolyl,
20 7-benzothiazolyl, 2-amino-7-benzothiazolyl,
2-acetamido-7-benzothiazolyl, 2-methyl-7-benzothiazolyl,
2,3-dihydrobenzofuran-5-yl, 2,3-benzodioxl-5-yl, 6-
indazolyl, 6-quinolinyl, and 6-quinoxalinyll.

- 25 6. A compound according to Claim 5 wherein R⁴ is
selected from the group consisting of 4-aminophenyl,
3-amino-4-methylphenyl, 6-indazolyl, 6-benzothiazolyl,
2-methyl-6-benzothiazolyl, 2-amino-6-benzothiazolyl,
6-quinolinyl, and 6-quinoxalinyll.

30

7. A compound of claim 1 with the stereochemistry as
designated in Formula Ia.

75







Ia







8. A compound according to Claim 1 wherein m is 1.







5







9. A compound according to Claim 1 selected from the group consisting of




10









or a pharmaceutically acceptable salt thereof.

5

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

10 11. A method for inhibiting HIV protease comprising administering a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

15 12. A method for treating HIV infection comprising administering a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

20 13. The method of claim 12 comprising co-administering a therapeutic amount of an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, or a combination thereof.

14. A method for treating AIDS or ARC comprising administering a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

5

15. The method of claim 14 comprising co-administering a therapeutic amount of an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, or a combination thereof.

10